Source link : https://www.newshealth.biz/health-news/early-promise-for-pi3k-inhibitor-in-brain-metastases/
HOUSTON — Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus radiation therapy (RT), a small phase I study showed. Eight of 12 evaluable patients had intracranial responses (all partial) to the dual-modality treatment, supporting the hypothesis that targeted PI3K inhibition has synergy with […]
Author : News Health
Publish date : 2024-11-25 17:09:22
Copyright for syndicated content belongs to the linked Source.